Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study

CONCLUSION: Despite improved efficacy of 1L systemic therapies, CSEs remain a concern for patients with uHCC, as well as an economic burden to the healthcare system. Newer treatments that reduce the risk of CSEs, while improving long-term survival in patients with uHCC, are warranted.PMID:38443649 | DOI:10.1007/s12325-024-02790-4

Source: Adv Data - March 5, 2024 Category: Epidemiology Authors: Daniel J Simmons Stephen J Valerio Darren S Thomas Marcus J Healey Zhuoxin Jiang Jesica M Levingston Mac Leod Yian Lin Janvi Sah Source Type: research